| |

Cracking the Code: Calretinin’s Role in Understanding Mesothelioma

ByHolly Zink
Cracking the Code: Calretinin's Role in Understanding Mesothelioma

Mesothelioma is a tough cancer that is hard to figure out. Scientists are looking at a protein called Mesothelin that could help. This protein might be a clue to the cancer, but we need an easier way to check it. In this study, scientists dig into Mesothelin, see how it affects cancer, and introduce a new way to look at it without being too invasive.

Breaking Down Mesothelin and How It Works

Results of this new study found that Mesothelin is higher in one type of mesothelioma and keeps going up as the cancer grows. This type is called the epithelial kind. When Mesothelin goes up, it makes certain things in the cancer cells increase. This makes the cancer cells move more and invade other parts, leading to a lower survival time.

To make things easier, scientists created tiny things called Mesothelin-targeted nanoprobes. These are special tools for checking Mesothelin without going inside the body. Scientists use them with MRI scans to learn more about Mesothelin.

Exciting Findings with Mesothelin-Targeted Nanoprobes

New data from this study showed that nanoprobes are good at checking Mesothelin. As scientists used more of them, they saw clear changes in epithelial-type mesothelioma. Scientists also tried this techniquen out on mice. The nanoprobes worked well again, showing different results over time, especially in the epithelial type. This matches how Mesothelin changes during the cancer’s different stages.

This study helps us learn more about how Mesothelin affects mesothelioma. The best part is that we now have a new way to check Mesothelin without being too invasive. This could help find the cancer early, tell us what type it is, and show how it’s growing. As scientists keep figuring out mesothelioma, tools like these nanoprobes bring us closer to better ways of finding and fighting this tough cancer.

Source:

Huang, Yilong, Shasha Shen, Jie Xiao, Cici Luo, Jiyao Ma, Xin Huang, Tianfu Qi, et al. “Mesothelin-Targeted MRI for Assessing Migration, Invasion, and Prognosis in Malignant Pleural Mesothelioma.” CANCER NANOTECHNOLOGY 15, no. 1 (December 2024): 1. https://doi.org/10.1186/s12645-023-00238-y.

Similar Posts

Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma
| |

Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

ByAlex Strauss

A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

Does Radiotherapy Reduce Mesothelioma Pain?
| |

Does Radiotherapy Reduce Mesothelioma Pain?

ByAlex Strauss

A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

Ape Virus Shrinks Mesothelioma Tumors in Lab
|

Ape Virus Shrinks Mesothelioma Tumors in Lab

ByAlex Strauss

A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

Radiotherapy for Mesothelioma: Better But Still Limited
| |

Radiotherapy for Mesothelioma: Better But Still Limited

ByAlex Strauss

A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

A Second-Line Option for Mesothelioma?
| |

A Second-Line Option for Mesothelioma?

ByAlex Strauss

Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

Mesothelioma Blood Test May Be Possible
|

Mesothelioma Blood Test May Be Possible

ByAlex Strauss

An international team of researchers is studying the proteins found on the surface of cancer cells in an effort to improve mesothelioma diagnosis. The team, made up of scientists from the US, Switzerland, Italy and Chile, has just published their findings on a new kind of test to identify protein-derived mesothelioma biomarkers in blood serum. Mesothelioma is an aggressive cancer of the membranes around organs. Because the most common mesothelioma biomarker, mesothelin, is also overproduced by other kinds of cancer cells, it has only limited diagnostic value. A test to identify a set of proteins produced specifically by mesothelioma cells could greatly improve diagnostic accuracy. Led by Ferdinando Cerciello and Bernd Wollscheid of the Institute of Molecular Systems Biology in…